| Document |
Document Title |
|
WO/2015/088045A1 |
The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the ...
|
|
WO/2015/086525A1 |
A series of tricyclic benzimidazole derivatives, in particular dihydro-1H- imidazo [1,2-a]benzimidazo le, dihydro-1H-pyrrolo [1,2-a]benzimidazo le, dihydro-1H- pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and...
|
|
WO/2015/086078A1 |
The present invention relates to indolizine-based materials as energy storage materials in an electrochemical energy storage device. In preferred embodiments, said indolizine-based materials are obtained by electropolymerization, or chem...
|
|
WO/2015/078417A1 |
Provided is a compound as represented by formula I, or pharmaceutically acceptable salt, hydrate or solvate thereof. Also provided in the present invention are new uses of the compound or the pharmaceutically acceptable salt, hydrate or ...
|
|
WO/2015/075598A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R2...
|
|
WO/2015/075665A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2015/067108A1 |
Disclosed is ringlike flavone shown by the formula (I), or an isoflavone compound, or nitric oxide, hydrate, solvate, or metabolite thereof, or pharmaceutically accepted salt or prodrug. A2 is -O- when A is -C(O)-; A2 is -C(O)- when A is...
|
|
WO/2015/067770A1 |
The present invention encompasses compounds of general formula (I), wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of di...
|
|
WO/2015/064558A1 |
This invention addresses the problem of providing the following: an organic electroluminescent element that has a high luminous efficacy and excels in terms of drive voltage and stability; and a display device and an illumination device ...
|
|
WO/2015/063046A1 |
The present invention relates to compounds of formula (I), which are characterized in that they are substituted by benzimidazo[1,2-a]benzimidazo-5-yl and/or benzimidazo[1,2-a]benzimidazo-2,5- ylene groups and in that at least one of the ...
|
|
WO/2015/064714A1 |
The present invention provides a compound that has autotaxin-inhibiting activity and is represented by formula (I) (where R1, R2, R3, R4, and R5 are as defined in the description), a drug comprising the compound as an active ingredient, ...
|
|
WO/2015/059668A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacol...
|
|
WO/2015/060348A1 |
The present invention relates to a cyclic aminomethyl pyrimidine derivative and a pharmacologically acceptable salt thereof which have a highly selective action on a dopamine D4 receptor and are useful as a therapeutic agent for attentio...
|
|
WO/2015/058661A1 |
The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug ...
|
|
WO/2015/056771A1 |
[Problem] To provide a compound useful as a pharmaceutical composition for prevention and/or treatment of diseases such as schizophrenia. [Solution] The inventors developed the present invention upon investigating a pharmaceutical compos...
|
|
WO/2015/052321A1 |
A compound which is selected from A: and salts and solvates thereof.
|
|
WO/2015/052322A1 |
RJW/FP7067259 150 ABSTRACT A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N ...
|
|
WO/2015/043492A1 |
Provided herein are substituted urea derivatives or stereoisomers, geometric isomers, tautomers, N-oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions th...
|
|
WO/2015/043398A1 |
Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acce...
|
|
WO/2015/043364A1 |
The present invention relates to a novel compound of formula (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein R1 represents a substituted or unsubstituted aryl or heteroaryl; R2 represents an opti...
|
|
WO/2015/039612A1 |
The present invention relates to a compound inhibiting the kinase activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for ...
|
|
WO/2015/028850A1 |
Provided are cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infe...
|
|
WO/2015/023958A1 |
Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agoni...
|
|
WO/2015/022926A1 |
The objective of the present invention is to provide a novel compound which has a BTK inhibitory action and a cytostatic effect. Additionally, the objective of the present invention is also to provide a medicine useful for prevention and...
|
|
WO/2015/016195A1 |
Provided is a Wnt signaling inhibitor which contains, as an active ingredient, a fused heterocyclic compound represented by formula (IA) or a pharmaceutically acceptable salt thereof. (In the formula, n1A is 0 or 1; n2A and n3A are the s...
|
|
WO/2015/017407A1 |
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A4, A5, A6, A8, R1, R2, R3, R7and n of Formula I, indep...
|
|
WO/2015/011397A1 |
The invention relates to compounds of formula (I), wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description. The invention also relates to drugs containing same.
|
|
WO/2015/012328A1 |
A compound represented by formula (I) [In the formula, each symbol is as described in the specification.] or a salt thereof has a PDE2A inhibitory action and is effective as a preventive and therapeutic agent for schizophrenia, Alzheimer...
|
|
WO/2015/007669A1 |
The present invention relates to compounds of general formula (I), wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK)...
|
|
WO/2015/004381A1 |
The invention relates to the use, for manufacturing a polymer coating, of a compound of formula (I) wherein the R groupings, which are identical or different, are selected among H and CH3 groups; and x is an integer from 0 to 100, y is a...
|
|
WO/2015/004024A1 |
The present invention relates to substituted pyrazolopyridine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharm...
|
|
WO/2015/004105A1 |
The invention relates to novel benzyl-1H-pyrazolo[3,4-b]pyridines, to methods for the production thereof, to the use thereof alone or in combination for the treatment and/or prophylaxis of diseases, and to the use thereof for producing m...
|
|
WO/2015/004896A1 |
A compound comprising a structure containing at least two structures represented by formula (1) in the same molecule and in which at least two of the structures represented by formula (1) are directly bonded to each other by single bonds.
|
|
WO/2015/004075A1 |
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, dihydroquinoxalinones and dihydropyridopyrazinones of general formula (I), in which A, X, R1, R2, R3, R4, R5, R6, and n have the meanings indicated in the de...
|
|
WO/2015/001076A1 |
The present invention relates to a class of novel isothiazolo[4,3-b]pyridine derivatives and a method for their preparation, as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives ...
|
|
WO/2014/160689A9 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors.
|
|
WO/2014/201857A1 |
Provided are a class of five-membered heterocyclic pyridine compounds as represented by the following general formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a preparation method thereof, p...
|
|
WO/2014/202458A1 |
The present invention discloses compounds according to Formula I: Wherein R 1a, R 1b, R 2, R 4, R5, R 6, R 7, R 8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin...
|
|
WO/2014/198808A1 |
The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
|
|
WO/2014/190949A1 |
Provided are the compounds as shown by formula (I) or the stereoisomers thereof, or the pharmaceutically acceptable salts, esters, or solvates thereof, wherein A1, A2, A3, M, Y, X, R3, R5, R6, R7, Q and n are as defined in the descriptio...
|
|
WO/2014/191906A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (l) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a com...
|
|
WO/2014/191964A1 |
The field of this invention relates to novel cyclopropyl derivatives of the general formula (I) representing pharmaceutically applicable Vinca Rosea type alkaloid compounds, particularly having a cytostatic effect. The invention also is ...
|
|
WO/2014/187922A1 |
Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each...
|
|
WO/2014/189142A1 |
Provided is a method capable of manufacturing morpholino oligonucleotides efficiently and with high yields in a liquid phase synthesis method by using, as starting material, a morpholino nucleotide in which the 5'-position hydroxyl group...
|
|
WO/2014/188173A1 |
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemp...
|
|
WO/2014/184163A1 |
The invention provides compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2014/181813A1 |
The purpose of the present invention is to provide: a compound having excellent PKC inhibitory activity and is useful as a prophylactic or therapeutic agent for immunologic diseases and inflammatory diseases, etc.; or a salt thereof. The...
|
|
WO/2014/178008A1 |
The invention relates to antibacterial compounds of formula (I), wherein R1, U, V and A are as defined in the description, to pharmaceutical compositions containing them and uses of these compounds in the manufacture of medicaments for t...
|
|
WO/2014/177527A1 |
The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2014/177490A1 |
The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
